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Systemic arterial hypertension in children has traditionally been thought to be secondary in origin. Increased incidence of
risk factors like obesity, sedentary life-styles, and faulty dietary habits has led to increased prevalence of the primary arterial
hypertension (PAH), particularly in adolescent age children. PAH has become a global epidemic worldwide imposing huge
economic constraint on health care. Sudden acute increase in systolic and diastolic blood pressure can lead to hypertensive crisis.
While it generally pertains to secondary hypertension, occurrence of hypertensive crisis in PAH is however rare in children.
Hypertensive crisis has been further subclassiﬁed depending on presence or absence of end-organ damage into hypertensive
emergency or urgency. Both hypertensive emergencies and urgencies are known to cause signiﬁcant morbidity and mortality.
Increasingawarenessamongthephysicians,targetedatinvestigationofthepathophysiologyofhypertensionanditscomplications,
better screening methods, generation, and implementation of novel treatment modalities will impact overall outcomes. In this
paper, we discuss the etiology, pathogenesis, and management of hypertensive crisis in children. An extensive database search
using keywords was done to obtain the information.
1. Deﬁnitions andEpidemiology
Primary arterial hypertension is a global epidemic aﬀecting
predominantly adult population [1]. Although secondary
etiologies of hypertension predominate in children, the
prevalenceofprimaryarterialhypertensionhasbeenincreas-
ing at an alarming rate particularly in adolescents and older
children[2].RecentsurveyconductedbytheNationalHealth
and Nutrition Examination Survey (NHANES) in 8–17-
year-old children showed a prevalence of prehypertension
and hypertension of about 10% and 4%, respectively,
with a higher incidence in African American and Mexican
Americans [3]. Increase in the prevalence of hypertension
has paralleled the increased prevalence of childhood obesity
[4]. Childhood obesity has increased by more than three
times in the past three decades [5]. The Fourth Report on the
Diagnosis, Evaluation, and Treatment of High Blood Pressure
in Children and Adolescents classiﬁed pediatric hypertension
into various stages [6]( Table 1). In one study the incidence
of stage 1 and 2 hypertension was reported to be 2.6%
and 0.6%, respectively, in adolescent students [7]. The Joint
National Committee on Detection, Evaluation, and Treatment
of Hypertension, JNC7, has labeled acute severe elevation
of blood pressure above 180/120mmHg (about 20mmHg
above the Stage II hypertension) as “Hypertensive Crisis”
in adults [8]. It is further subclassiﬁed based on presence
of target organ abnormalities like seizures, intracranial
hemorrhage, Posterior reversible encephalopathy syndrome
(PRES), focal neurological deﬁcit, congestive cardiac failure,
papilledema, retinal hemorrhages, and acute vision loss into
Hypertensive Emergency and in the absence of target organ
abnormalities as Hypertensive Urgency [8]. Unfortunately, no
such clear deﬁnition has been proposed for Hypertensive
Crises in children. Sequelae of hypertension emergencies
like left ventricular failure, encephalopathy, aortic dissection,
myocardial ischemia, acute renal insuﬃciency, and retinal
damage are well known in adults [9]. However, target organ
damage and adverse eﬀects have also been demonstrated
in older children and adolescents and are an evidence of
long-term blood pressure elevation [10–17]. In addition,2 International Journal of Nephrology
Table 1: Deﬁnitions of normal and elevated blood pressure in
children.
Normal blood pressure Systolic and diastolic blood pressure
below 90th centile
Prehypertension
Systolic or diastolic blood pressure
above the 90th centile (or 120/80
m m H g ) ,b u tb e l o wt h e9 5 t hc e n t i l e
Stage I hypertension
Systolic or diastolic blood pressure
higher than or equal to the 95th
centile, but lower than the 99th centile
plus 5 mm Hg
Stage II hypertension Systolic or diastolic BP higher than or
equal to the 99th centile plus 5 mm Hg
target organ damage has been reported even in neonates
and pediatric patients with prehypertension and white
coat hypertension, implying that any age and any level of
hypertension could result in long-term consequences. About
1% of all adults with a diagnosis of hypertension develop
Hypertensive crisis, of which 76% are hypertensive urgencies
and 24% are hypertensive emergencies [18]. Similar data in
childrenisnotavailable.Inaddition,althoughtheprevalence
of the primary hypertension has increased over the past
three decades, the incidence of hypertensive crisis is very
uncommon in pediatric patients with primary hypertension
and its occurrence is more common in pediatric patients
with secondary hypertension. Terminologies like Accelerated
Hypertension and Malignant Hypertension are obsolete and
should not be used.
Etiology. In adults, majority of the cases of hypertensive
crises are due to nonadherence to prescribed medication,
drug overdose, sudden withdrawal of antihypertensive med-
ications, and so forth [19–22]. In comparison, majority
of pediatric hypertensive crises are renal in origin [23].
Interestingly, etiologies also diﬀer according to the patient’s
age, onset (acute versus chronic), and duration (inter-
mittent/episodic or persistent). For example, conditions
like coarctation of aorta, renal vein, or artery thrombo-
sis predominate in neonates. However, renal parenchymal
diseases, pregnancy, endocrine conditions, autoimmune
diseases, medications, drugs, and alcohol are important
etiologies in older children and adolescents. Conditions like
pheochromocytoma can present with episodic or sustained
hypertensionwhereaschronicglomerulonephritishaspersis-
tent/sustained hypertension (Table 2).
Pathophysiology and Pathogenesis. Blood pressure is a prod-
uct of cardiac output and peripheral vascular resistance
(PVR). Cardiac output is a product of heart rate and stroke
volume. In turn, stroke volume is determined by preload,
contractility, and after-load/PVR [24]. Figure 1 outlines the
various factors that determine the arterial blood pressure
(adapted with permission from [25]). Any factor which
enhances the heart rate and determinants of stroke volume
would result in hypertension. The pathogenesis of hyper-
tensive crisis is multifactorial and much of the supportive
Table 2: Causes of hypertension in children.
Renal
Congenital dysplastic kidneys
Multicystic kidney disease
Polycystic kidney disease
Hydronephrosis
Renal artery stenosis
Renal vein thrombosis
Glomerulonephritis
Acute tubular necrosis
Hemolytic-Uremic syndrome
Obstructive uropathy
Wilms tumor
Diabetic nephropathy
Pyelonephritis
Cardiovascular
Coarctation of aorta
Takayasu’s arteritis
Moyamoya disease
Endocrine
Cushing’s syndrome
Hyperthyroidism
Hyperparathyroidism
Congenital adrenal
hyperplasia
Pheochromocytoma
Medications,
drugs, and
toxins/poisons
Corticosteroids
Tacrolimus
Cyclosporine
Erythropoietin
Amphetamines
Oral contraceptives
Anabolic steroids
Phencyclidine
Vitamin D intoxication
Cocaine
Alcohol
Smoking
Lead, thallium, mercury
toxicity
Central nervous
system
Brain tumors
Intracranial hemorrhage
Raised ICP
Autonomic dysfunction
Neuroblastoma
Encephalitis
Autoimmune
Systemic lupus erythematosus
Polyarteritis nodosa
Rheumatoid arthritis
Goodpasture’s disease
Wegener’s Disease
Mixed connective tissue
disordersInternational Journal of Nephrology 3
Table 2: Continued.
Miscellaneous
Obesity
Pregnancy
IUGR
Umbilical artery
catheterization
Hypercalcemia
Hypervolemia
Pain
Drug withdrawal (opiates,
clonidine, beta-blocker)
Genetic
Gordon syndrome
Liddle’s syndrome
Turner’s syndrome
William’s Syndrome
Friedreich’s ataxia
Von Hippel-Lindau syndrome
Tuberous sclerosis complex
Neuroﬁbromatosis
Multiple endocrine neoplasia
data is based on both animal and human adult studies. The
factors that have been implicated in the pathogenesis include
elevated blood pressure, ﬂuid overload, sympathetic over-
activity, renin-angiotensin-aldosterone system activation,
oxidative stress, endothelial dysfunction, and inﬂammation.
There is a complex interaction between all these factors and
allorsomefactorsoccurringsimultaneouslymaybeinvolved
in the pathogenesis of hypertensive crisis.
2.ElevatedBlood Pressure
Complex interactions between renal, humoral, neural, and
cardiovascular systems are involved in the maintenance of
normal perfusion pressures to target organs during ﬂuctua-
tionsofbloodpressures[24].Anydisturbanceintheautoreg-
ulatory mechanisms results in mechanical stress resulting in
vascular injury and endothelial damage. Endothelial damage
thus initiates a cascade of proproliferative, prothrombotic,
and proinﬂammatory reactions, in addition to release of
vasoactive peptides. These cascades of events eventually
result in ﬁbrinoid necrosis and tissue ischemia. This cul-
minates into a vicious cycle of tissue ischemia potentiating
the blood pressure due to release of vasoactive peptides,
sympathetic overactivity, and ﬂuid retention leading to
further endothelial damage and inﬂammation which in turn
again worsen the tissue ischemia [26, 27].
3. Renin-Angiotensin-Aldosterone
System (RAAS)
RAAS plays an important role in the regulation of blood
pressure and during hypertensive crisis [28]. The enzyme
reninactsonangiotensinogen(AGT)togenerateangiotensin
I (Ang I). Ang I is further converted to angiotensin II (Ang
II) by angiotensin converting enzyme (ACE). Ang II exerts
its eﬀects by binding to two major types of receptors—AT1R
and AT2R[ 29]. Functions like vasoconstriction, cellular
proliferation, cellular hypertrophy, ﬁbrosis, atherosclerosis,
antinatriuresis, and release of aldosterone, endothelin, nore-
pinephrine, and vasopressin are initiated by binding of
Ang II to AT1R. In addition, Ang II induces mitochondrial
dysfunction via a protein kinase C-dependent pathway by
activating the endothelial cell NADPH oxidase and forma-
tion of peroxynitrite [30]. A recent study demonstrated that
Ang II stimulates increased IL-6 production both in vivo and
in vitro. In addition to its role in hypertension, increased
IL-6 may play an important pathogenic role in CKD by
Ang II-mediated induction of multiple ﬁbrotic genes and
ET-1 production leading to renal injury and ﬁbrosis [31].
In addition, recent identiﬁcation (Pro) Renin receptors and
functionally active Ang II-derived peptides like Ang 1–7 have
beenshowntoplaypathologicalroleincausinghypertension
[32].
4. Inﬂammation
Various inﬂammatory cytokines and chemokines have been
implicated in the pathogenesis of hypertension. Ang II
has been shown to be proinﬂammatory and proﬁbrotic by
inducing and activating various inﬂammatory pathways and
upregulating cytokines, chemokines, and NFKB. The pivotal
role of various T-cell subsets and macrophages in the regu-
lation of blood pressure and target organ damage has been
demonstrated in recent studies [33–38]. Amelioration of
the target organ damage by immune-suppressant treatment
further conﬁrms involvement of immune mediators in the
pathogenesis of hypertension. Ang II also facilitates recruit-
ment of leukocytes through the endothelium by induction
of ICAM-1 and VCAM-1 [39, 40]. T lymphocytes CD4 (+)
and, to a lesser extent, CD8 (+) have been demonstrated to
mediate the accelerated microvascular thrombosis associated
with Ang II-induced hypertension [41]. Although the exact
mechanism is unclear, it is thought to be secondary to
complex interaction between platelets and cytokines result-
ing in activation of coagulation cascade. In addition, the
presence of NADPH oxidase-derived reactive oxygen species
also facilitates prothrombotic action of Ang II [41]. Recent
study also demonstrated immunosuppressive properties of
regulatory T cells (Treg) when adaptive transfer of isolated
Treg cells into Ang II–infused mice resulted in amelioration
of cardiac damage [42].
5. OxidativeStress and
Endothelial Dysfunction.
Nitric oxide (NO) is synthesized by endothelial nitric oxide
synthase (eNOS) in the vascular endothelium from its
precursormoleculeL-arginine.NOinthepresenceofsoluble
guanylate cyclase (sGC) results in increased intracellular
levelsofcyclicGuanosinemonophosphate(cGMP).Elevated4 International Journal of Nephrology
cGMP causes decrease in intracellular calcium ion levels
leading to decreased vascular tone. Oxidative stress may play
a causal role in the development of hypertension by altering
the vascular tone either by oxidative modiﬁcation of proteins
and nucleic acids or by decreasing the bioavailability of nitric
oxide. Superoxide anions generated by various enzymes such
as NADPH oxidase, xanthine oxidase, and enzymes involved
in mitochondrial respiratory chain may directly inactivate
NO and inhibit sGC. Increased angiotensin II levels facilitate
further generation of superoxide anions by stimulating these
enzymes. In addition, superoxide anions lead to uncoupling
of eNOS by oxidating the BH4 (tetrahydrobiopterin). BH4
is an essential cofactor necessary in generation of NO by
eNOS enzyme. Uncoupling of eNOS also facilitates further
generation of superoxide anions. These superoxide anions
cause increased vascular cell proliferation and migration,
apoptosis, inﬂammation, extracellular matrix alterations,
and endothelial dysfunction [43–46].
6. Central Nervous System
The role of central nervous system in the regulation of blood
pressureviamodulationofsympatheticandparasympathetic
nervous system is well known. However, recent studies
suggest that increased sodium intake results in increase in
endogenous ouabain (EO) levels in the paraventricular and
supraoptic nuclei and at the circumventricular organs such
as subfornical organ. This induces an acute but transient
Ang-II-mediatedincreaseinperipheralsympatheticnervous
systemresultinginelevationinbloodpressures.Experiments
conducted in rats reveal complex interactions involving
sodium ions, epithelial sodium channels (ENaCs), RAAS,
and EO in the brain which activate sympathetic nervous
system. Thus, a brain Na+-ENaC-RAAS-EO pathway and a
neuromodulatorypathwayinvolvingAldosterone-EO-AngII
have been proposed in explaining the mechanism of action
of hypertension. Further research and understanding of
these novel mechanisms will help in newer antihypertensive
therapies [47].
In addition, genetic mutations and polymorphisms [48],
and insulin resistance [49], and abnormalities involving
the sodium transport mechanisms like Na+/H+ exchanger,
Na+/K+/2Cl− cotransporter, Na+Cl− cotransporter, Na+/K+
ATPase, and sodium-phosphate cotransporter [50, 51]h a v e
also been implicated in the pathogenesis of hypertension.
A possible mechanism of hypertensive crisis is shown in
Figure 2.
6.1. Clinical Features and Target-Organ Damage. Clinical
presentation varies depending upon age, the target organ
involved, and etiology. Neonates may present with apnea,
cyanosis, irritability, and poor feeding [52].In addition,
clinical features may reﬂect speciﬁc etiologies like endocrine
diseases, autoimmune conditions, pregnancy, and drug
abuse. Older children with long-term hypertension or acute
exacerbation of chronic hypertension or sudden severe
elevation of blood pressure may present with symptoms
related to end organ abnormalities involving the heart, eye,
kidney, and brain [53].
6.2. Cardiovascular Manifestations. Depending on the dura-
tion and acuity of the symptoms, the cardiac involvement
can be in the form of left ventricular hypertrophy (LVH),
left ventricular failure, or left ventricular ischemia [54, 55].
Although left ventricular hypertrophy has traditionally been
deﬁned in pediatric population as left ventricular mass index
(LVMI) greater than 38.6g/m2.7 and has been recommended
in the fourth report, a recent study has demonstrated that
LVMI varies signiﬁcantly in children particularly those <9
years of age. The study which was performed in 2,273
nonobese, healthy children demonstrated that in children
aged >9 years the 50th percentile values of LVMI ranged
from 27g/m2.7(girls) to 32g/m2.7(boys) and varied little with
age. The 95th percentile values of LVMI in the >9y e a r s
age group ranged from 40g/m2.7(girls) to 45g/m2.7(boys).
The authors concluded that values >40g/m2.7in girls and
>45g/m2.7 in boys should be considered abnormal. In
contrast, the 50th percentile values of LVMI in children <9
years age group varied signiﬁcantly from 56.44g/m2.7(boys)
and 55.38g/m2.7(girls) in infants less than 6 months of
age to 31.79g/m2.7(boys) and 29.71g/m2.7(girls) in children
less than 8years of age. Similarly, the 95th percentile
values of LVMI in the <9y e a r sa g eg r o u pv a r i e df r o m
80.1g/m2.7(boys) and 85.6g/m2.7(girls) in infants less than
6 months of age to 44.6g/m2.7(boys) and 43.5g/m2.7(girls) in
childrenlessthan8yearsofage(Table 3).Thisstudyprovides
normal percentile values for young children and emphasizes
the need for age–appropriate LVMI cut points and use
of appropriate percentile curves particularly in children
<9y e a r so fa g e[ 56]. The LVH is common in children
with hypertension with an incidence of 41.1% particularly
in children with high Body-Mass index (BMI) and in
Hispanic population [57]. Left ventricular failure can lead
to symptoms such as increased work of breathing, shortness
of breath, chest pain, palpitations, decreased urine output,
and poor appetite. Sudden acute increase in blood pressure
may precipitate left ventricular failure in any pediatric age
group but is more commonly reported in neonates [58–60].
Carotid intima media thickness (CIMT), measured by B-
mode ultrasound at end diastole, has emerged as a surrogate
marker of early atherosclerotic changes and is predictive of
adult cardiovascular structural damage. Indeed, increasing
number of studies in children with hypertension, dyslipi-
demia, diabetes, and obesity have shown an increased CIMT.
However, a recent study showed that nonobese children
with primary hypertension had increased CIMT compared
with BMI-matched controls. Although obesity may play
a signiﬁcant role in vascular changes, this study provides
strong and interesting evidence that CIMT may be increased
in nonobese children with primary hypertension. The major
drawbackofthissurrogatemarkeristhatthereferencevalues
are not available for children younger than 10 years and
further studies are needed to determine reference values of
CIMT in this age group [61–63].
6.3. Neurological Manifestations. Loss of cerebral autoreg-
ulation leading to disruption of the blood brain barrier
and endothelial dysfunction results in imbalance in oxygen
delivery, edema formation, and microhemorrhages [64].International Journal of Nephrology 5
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Figure 1: Factors that determine the arterial blood pressure (adapted with permission from [25]).
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myo-proliferation
Further increase in blood 
pressure
Figure 2: Mechanism of hypertensive crisis.
Table 3: Age-speciﬁc reference values of the LVMI in boys and girls Adapted from [56].
Age Sex LVMI (50th percentile) LVMI (95th percentile)
>9 years Boys 32.0 g/m2.7 45.0 g/m2.7
Girls 27.0 g/m2.7 40.0 g/m2.7
<8 years Boys 31.79 g/m2.7 44.6 g/m2.7
Girls 29.71 g/m2.7 43.5 g/m2.7
<6m o n t h s Boys 56.44 g/m2.7 80.1 g/m2.7
Girls 55.38g/m2.7 85.6 g/m2.76 International Journal of Nephrology
These changes may lead to seizures, altered mental status,
PRES, vomiting, signs of raised intracranial pressure, focal
neurological deﬁcits, and headache. Headache is the most
common symptom [65–69]. In one study seizures occurred
in 25% of children, encephalopathy in 25%, facial palsy
in 12%, and hemiplegia in 8% [18]. Posterior reversible
encephalopathy syndrome has been reported to predomi-
nantly aﬀect the occipitoparietal white matter with occa-
sional spread to basal ganglia, cerebellum, and brainstem.
Various etiologies like post-chemotherapy, posttransplant,
postinfectious, autoimmune conditions, and posthyperten-
sive crisis have been known to cause PRES. Clinical features
include headache, altered mental status, nausea, vomiting,
seizures, cortical blindness, and focal neurological deﬁcits.
Magnetic Resonance Imaging shows bilateral, symmetrical,
involvement of white matter in occipitoparietal regions
which appear as hyperintense lesions on T2-weighted images
andhypointenseorisointenselesionsonDiﬀusion-Weighted
Images. PRES is a completely reversible condition with
occasional reports of neurological deﬁcits [70–72].
6.4. Renal Manifestations. Hematuria, ﬂank pain, and olig-
uria would indicate renal involvement. The most common
etiology leading to hypertension in children is renal disease
but hypertension itself can result in renal injury and failure
secondary to loss of autoregulation of renal blood ﬂow.
But the data exploring the impact of hypertension on the
renal function and structural injury in pediatric population
is limited. Histologically ﬁbrinoid necrosis with thrombosis
involving the intrarenal arteries has been demonstrated in
adult studies which result in clinical presentation consistent
with microangiopathic hemolytic anemia [73, 74]. A recent
study, however, has demonstrated increased microalbumin-
uria and decreased glomerular ﬁlteration rate in prehyper-
tensive children particularly with high blood pressure load
[75]. In addition, another study demonstrated a reduction
in microalbuminuria and LVH when hypertension was
controlled with ACE inhibitors [76]. These ﬁndings suggest
that renal dysfunction and structural injury may occur early
eveninpediatricpopulationwithhypertensionandcontinue
into adult life and studies are needed to further elucidate
these ﬁndings.
6.5. Ophthalmological Manifestations. Retinal bleeds,
papilledema, loss of visual acuity, acute ischemic optic
neuropathy, and cortical blindness have been reported
secondary to hypertensive crisis [77]. Loss of vision can
be serious and permanent. Traditionally hypertensive
retinopathy assessed by direct fundoscopy has been
described based on Keith-Wagner-Barkar’s classiﬁcation
(1939) which was subsequently modiﬁed by Scheie (1953)
[78, 79]. The major drawback of these classiﬁcations is that
direct fundoscopic examination is limited by physician’s
experience and high inter- and intraobserver variability.
More recently Wong and Mitchell (2004) (Table 4) proposed
a new classiﬁcation which stratiﬁed cardiovascular risks
associated with diﬀerent grades of hypertensive retinopathy
in adults [80]. The data regarding the prevalence of
hypertensive retinopathy in general pediatric population is
largely unknown. However, in two studies the prevalence
of hypertensive retinopathy in children with hypertension
varied from 8.9% (assessed by direct fundoscopy) to 50%
(assessed by retinal photographs) [13, 81]. Majority of the
children in both studies had mild retinopathy and none had
higher-grade retinopathy. In addition, evidence of grade III
and grade IV hypertensive retinopathy was lacking in 32%
of adults with hypertensive encephalopathy [82]. Although
many studies involving the risk stratiﬁcation and prognostic
importance based on the retinopathy grades are available
in adults, no such data exists in pediatric population.
In general, moderate-to-severe grades of retinopathy are
relatively rare in children and further studies are needed to
elucidate the importance of mild retinopathy and long-term
prognosis. But newer techniques like digital imaging and
computer analysis of the early retinal changes and newer
grading systems will further help in risk stratiﬁcation and
disease progression [83].
7. ClinicalAssessment
Clinical assessment begins with obtaining relevant present,
past medical history. Potential risk factors include history of
low birth weight, intrauterine growth retardation, prema-
turity, oligo or polyhydramnios, umbilical artery catheter-
ization, recurrent urinary tract infections, weak stream of
the urine in male child, hematuria, ﬂank pain, polyuria,
failure to thrive, joint pains, skin rashes, headaches, visual
disturbances, chest pain, palpitations, and poly or oliguria.
Family history of diabetes, hypertension, obesity, hyperc-
holesteremia, early strokes, coronary artery diseases, sudden
cardiac deaths, malignancies, autoimmune conditions, or
hereditary conditions involving the kidneys, liver, and brain
should be assessed. A detailed endocrine-related history
should also be obtained. Medication history involving
steroids, antihypertensives, tacrolimus, cyclosporine, oral
contraceptives, and dietary and life-style history regarding
smoking, alcohol, and drug abuse should be elucidated.
In addition in teenage adolescent girls, pregnancy-related
symptoms should be elicited. In obese children, history of
sleep apnea and daytime somnolence should be obtained.
Physical examination should involve general exami-
nation to look for edema, skin rashes, neurocutaneous
markers, cyanosis, elﬁn facies, webbing of neck, hirsutism,
cushingoid features, thyroid enlargement, proptosis, and
so forth. Heart rate, respiratory rate, and four-extremity
blood pressure preferably both in lying and sitting posi-
tion, peripheral pulses, height, weight, and BMI should be
recorded. A detailed cardiovascular, respiratory, abdominal,
and neurological examination should be performed to look
for any evidence of coarctation, LVH, pulmonary edema,
pleural, and pericardial eﬀusions. In addition, examine for
hepatosplenomegaly, intra-abdominal masses, ascites, and
genitourinary abnormalities. Look for any evidence of spina
biﬁda, hydrocephalus, signs of raised ICP, papilledema, focal
neurological deﬁcits, and cranial nerve palsies particularly
3rd and 7th cranial nerves.International Journal of Nephrology 7
Table 4: Wong and Mitchell’s classiﬁcation (adapted from [80]).
Grading Retinal signs Sytemic associations∗
Mild retinopathy
Generalized arteriolar narrowing, focal
arteriolar narrowing, arteriovenous
nicking, opacity (copper wiring) of
arteriolarwall, or a combination of
these signs
Modest association with risk of clinical
Stroke, subclinical stroke,coronary
heart disease, and death
Moderate retinopathy
Hemorrhage (blot, dot, or ﬂame
shaped), microaneurysm cotton-wool
spot, hard exudates or a combination
of these signs
Strong association with risk of clinical
stroke, subclinical stroke, cognitive
decline, and cardiovascular mortality
Severe retinopathy Moderate retinopathy plus optic disc
swelling # Strong association with mortality
∗A modest association is deﬁned as an odds ratio of greater than 1 but less than 2. A strong association is deﬁned as anodds ratio of 2 or greater.
#Anterior ischemic optic neuropathy, characterized by unilateral swelling of the optic disk, visual loss, and sectorial visual ﬁeld loss, should be ruled out.
Table 5: Initial workup for hypertension.
Complete blood count
Basic metabolic panel including magnesium and phosphate
Serum uric acid
Fasting lipid proﬁle
Fasting blood glucose
Urine analysis/culture
Urine electrolytes, creatinine, protein
Chest X-ray
EKG and echocardiogram
Renal ultrasound with doppler
8.LaboratoryWorkupandEvaluation
Successful management of the elevated blood pressure in
childrendepends ontheaccuratediagnosis andevaluationof
theetiology of hypertension. Itis wellknown thatthe clinical
spectrum of the etiology of hypertension is varied depending
on the age of the child. Thus, it is vitally important that after
a thorough history and physical examination, an extensive
laboratory workup should be undertaken particularly in
a young child who has extremely high pressure to rule
out secondary causes of hypertension. In addition, workup
should include tests and imaging studies to rule out end-
organ damage. Some of the common initial workup and
advanced investigatory studies based on the etiology have
been outlined (Tables 5 and 6).
9. Treatment
Prompt recognition and treatment is of utmost importance
to prevent target organ damage. Hypertensive emergency in
children or adults is an indication for admission to intensive
care unit for close monitoring and prompt initiation of
appropriate intravenous antihypertensive therapy depending
upon the etiology. Blood pressure should be preferably
monitored continuously by invasive intra-arterial line or
intermittently by noninvasive methods if intra-arterial line
Table 6: Further workup if needed depending upon the etiology.
TSH, Free T4. Free T3
Serum cortisol
Serum aldosterone
Serum renin levels
HbA1C
24 hr urinary catecholamine and metanephrine levels
(Pheochromocytoma)
Serum parathyroid hormone levels
Urine and serum toxicology screen
Urine pregnancy test
CT/MRI scan
DMSA/DTPA scan (renal scars)
MIBG scan (pheochromocytomas)
ANA/ESR/CRP/anti-dsDNA/anti-smith/rheumatoid
factor/pANCA/cANCA
cannot be obtained for any reason. Patient’s cardiac, respira-
tory, and neurological status should be constantly monitored
and prompt interventions implemented in case of any dete-
rioration. Hypertensive urgency may be managed on regular
pediatric unit and with oral antihypertensive medications.
Moving the patient to intensive care unit may be considered
in case of worsening of clinical condition (Figure 3). As per
theFourthReportontheDiagnosis,Evaluation,andTreatment
of High Blood Pressure in Children and Adolescent, the
primary aim of antihypertensive treatment is to reduce the
blood pressure to <95th percentile and to <90th percentile in
thepresenceofcomorbidconditionslikediabetes,cardiac,or
renal disease. Furthermore, the mean arterial blood pressure
should be lowered no more than ≤25% of the initial value
in the ﬁrst 1hr and a gradual reduction should be obtained
over the next 24–48hrs to normalize the blood pressure [6].
However, no clear guidelines exist about the rate of lowering
the blood pressure in the presence of ischemic stroke.
Majority of the randomized clinical trials and data
on anti-hypertensive medications are obtained from adult
studies.Dataregardingthesafety,eﬃcacy,andadverseevents8 International Journal of Nephrology
Hypertensive crisis
Hypertensive emergency Hypertensive urgency
Admit to PICU
Target organ damage
Yes No
Consider intra-arterial blood pressure 
monitoring  and commence immediate 
and appropriate IV antihypertensive 
treatment depending on the cause
Decrease blood pressure carefully 
by about 25% of the initial value in  
the ﬁrst 8 hours
Gradual reduction of blood 
pressure to about 90th centile for   
age  in the next 48 hours 
Blood pressure stable, change to oral 
antihypertensive medications, and  
discontinue continuous intra-arterial 
blood pressure monitoring
Admit to pediatric ﬂoor
Frequent noninvasive blood 
pressure monitoring and  
treatment using oral anti
hypertensive medications
Worsening of 
blood pressure
Normalization or good 
control of blood pressure
Review medications, ensure 
compliance  education and 
prevention of risk factors, and 
close out-patient follow-up
Figure 3: Proposed algorithm for the management of hypertensive crisis in children.
about most of the anti-hypertensive agents is not available
in pediatric population and is either extrapolated from adult
clinical trials or has been limited to expert opinions. Some
of the intravenous antihypertensive medications used in
the treatment of hypertensive emergencies include sodium
nitroprusside, nicardipine, esmolol, hydralazine, labetalol,
fenoldopam, and phentolamine. Some of the medications
used in the treatment of hypertensive urgencies include
enalapril, nifedipine, clonidine, minoxidil, and angiotensin
II receptor blockers. In our institute depending upon the
etiology and contraindications, we prefer to use sodium
nitroprusside, nicardipine, and esmolol as our ﬁrst, second,
and third choices in the management of hypertensive
emergency. In case of hypertensive urgencies, we prefer to
use amlodipine, nifedipine, ACE inhibitors, angiotensin II
receptor blockers, labetalol, or clonidine either alone or in
combination. The details of the mechanisms of action and
adverse eﬀects are outlined in Table 7. However, the results
of a recent Cochrane review showed that there is no evidence
demonstrating that antihypertensive drugs reduce mortality
or morbidity in patients with hypertensive emergencies. The
authors were unable to determine which drug or drug class
is most eﬀective in reducing mortality and morbidity. The
authors concluded that RCTs are needed to assess diﬀerent
drug classes to determine initial and longer-term mortality
and morbidity outcomes [84]. In the next section, we have
summarized the management of hypertension crisis in some
of the important pediatric conditions which we think may be
more useful to the clinicians.
9.1. Hypertensive Crisis due to Medications or Drugs. Sudden
cessation of opiates, benzodiazepines, and clonidine can also
lead to withdrawal syndrome and present with hypertensive
crisis. Reintroduction of medications causing the withdrawal
followed by gradual weaning of the medications will result in
resolution of hypertensive crisis in most cases. Cocaine toxi-
city is a well-known cause of hypertensive crisis particularly
among adolescents. Mechanism of hypertensive crisis due
to cocaine toxicity involves potentiation of catecholamine
eﬀects by inhibition of the presynaptic uptake of nore-
pinephrine. Intravenous alpha-blocker like phentolamine is
treatment of choice and beta-blockers may be added if
needed later in the treatment [85–87]. Hypertensive crisis
is also known to occur when medications like monoamine
oxidase inhibitors interact with food containing tyramine
and other medications like dextromethorphan, methylene
blue, selective serotonin reuptake inhibitors, and linezolid.
Hypertension due to MAOI interaction can be treated with
either an alpha blocker or sodium nitroprusside [88–91].
Hypertensive crisis due to amphetamine toxicity is due to
sympathomimeticandserotonergiceﬀectsofamphetamines.
In addition to decontamination, cooling, sedation, intra-
venous alpha-blockers, or sodium nitroprusside is the treat-
ment of choice [92, 93]. Beta-blockers alone are absolutely
contraindicated in all these toxidromes as they will worsen
the hypertensive crisis due to unopposed action on alpha
receptors.
9.2. Hypertensive Crisis due to Pheochromocytoma. Pheo-
chromocytoma is rare tumor arising fromchromaﬃnc ell si n
the adrenal medulla and extra adrenal paraganglionic tissue
in children. About 80% of the pheochromocytomas arise
from adrenal medulla in children. Approximately 40% ofInternational Journal of Nephrology 9
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pheochromocytomas are associated with genetic mutations
and about 19–38% are bilateral. About 1% of pediatric
hypertensive patients have pheochromocytoma with a peak
incidence at around 11 years. But it is more commonly
diagnosed in adults with a peak incidence between 4th
and 6th decade of life. Multiple endocrine neoplasia type
2, Von Hippel-Lindau syndrome, neuroﬁbromatosis type
1, and germline mutations of succinate dehydrogenase
(SDH) gene are some of the common causes of heredi-
tary pheochromocytomas. Clinical presentation of pediatric
pheochromocytomaisvariedandrangesfromasymptomatic
to sustained hypertension in about 60–90%. Paroxysmal
hypertension is less common when compared to adults
and its presence should raise a suspicion of pheochro-
mocytoma. Children with dopamine secreting pheochro-
mocytomas are usually normotensive. Symptoms such as
headache, palpitations, sweating, vomiting, pallor, weight
loss, polyuria, visual disturbances, anxiety, and attention
deﬁcit-hyperactivity are common presenting features in
children. Quantiﬁcation of plasma-free metanephrine and
normetanephrine based on age-speciﬁc reference intervals
and 24 hr urinary-fractionated metanephrines preferably
in supine position are most sensitive diagnostic tests for
pheochromocytoma. After the biochemical conﬁrmation of
the diagnosis, tumor localization studies like magnetic reso-
nance imaging (MRI), 123metaiodobenzylguanidine (MIBG)
scintigraphy, and occasionally in rare cases studies like
[111In]-Octreotide scintigraphy, [18F]-ﬂuorodopamine, or
[18F]-ﬂuorodeoxyglucose positron emission tomography
(FDG-PET) may be required. Surgery is the treatment
of choice but good preoperative medical management of
hypertension for at least 10–14 days is recommended.
Adequate perioperative management of hypertension will
result in decrease in postoperative complications. α2-
blockade with noncompetitive α2-blocker like phenoxyben-
zamine is the medication of choice. For localized tumors
laparoscopic cortical-sparing adrenalectomy is the preferred
surgery in children. Treatment options for invasive and
metastatic tumors include embolization, systemic therapy
with 131MIBG, or chemotherapy [94–97].
9.3. Hypertensive Crisis due to Renovascular Disease. Ren-
ovascular hypertension is an uncommon but important
cause of correctable hypertension in children. 3–10% of
the children evaluated for hypertension are found to have
renovascular hypertension. Unlike atherosclerosis which is
the most common cause of renovascular hypertension in
adults,themostcommonetiologyoftherenovasculardisease
in children in Western countries is ﬁbromuscular dysplasia.
On the contrary, in developing Asian countries and South
Africa, Takayasu’s arteritis is the most common cause and is
probably related to high incidence of tuberculosis in these
countries. The other important etiologies of renovascular
disease include syndromes like William’s syndrome, Marfan’s
syndrome, Neuroﬁbromatosis type 1, rubella syndrome,
tuberous sclerosis, Klippel Trenaunay Weber syndrome,
Linear sebaceous nevus syndrome and vasculitides like
Kawasaki’s disease, and Polyarteritis nodosa. In addition,
extrinsic compression due to neuroblastoma, Wilms’ tumor,
and other tumors may lead to renal artery stenosis (RAS).
Miscellaneous causes of RAS include irradiation, Crohn’s
disease, postrenal transplant, trauma and umbilical artery
catherization. Children with the aforementioned conditions
and hypertension should be meticulously evaluated for RAS.
In addition, children with severe hypertension which is
unresponsive or uncontrolled with multiple antihyperten-
sion medications or have renal arterial bruit, absent pulses,
hypokalemia, elevated plasma renin activity, and unequal
sizes of kidneys on ultrasound should also be investigated
for RAS. RAS can be unilateral or bilateral, extrarenal, or
intrarenal or both. Incidence of bilateral RAS is higher than
unilateralRAS.Itisimportanttoknowthatrenalarterybruit
isaninfrequentﬁndingandmaybeabsentinasmanyas70%
of the patients with RAS. Although renal arteriography is the
gold standard in the investigation of RAS, other less invasive
methods like Doppler ultrasonography, magnetic resonance
angiography, computerized tomographic angiography, cap-
topril renography, and digital substraction angiography may
be used initially. CO2 angiography has been advocated
in patients with renal insuﬃciency to minimize contrast-
induced renal injury but pediatric experience is limited.
When the index of suspicion is high or when noninvasive
methods have been tried, invasive techniques like renal
arteriography and renal vein renin assays can be obtained to
conﬁrm the diagnosis. In the presence of unilateral disease
a renal vein renin ratio of >1.5 between the aﬀected and
nonaﬀected kidney is considered signiﬁcant. In absence of
any diﬀerence in the ratios bilateral RAS may be suspected.
Treatment depends upon the etiology, severity, and extent of
the disease. In cases of RAS secondary to Takayasu’s arteritis
steroids, immunosuppressive therapy and antituberculous
treatment are the mainstay. In general it is advisable to
avoid diuretic therapy as it may increase plasma renin
levels secondary to volume depletion. In children who have
RAS which is amenable to surgical treatment, percutaneous
transluminal renal angioplasty, stenting, segmental ethanol
ablation, revascularization, and partial or total nephrectomy
of the aﬀected kidney are some of the options. In selected
cases with diﬀuse and extensive bilateral intrarenal arterial
lesionswheresurgicalcorrectioncannotbeperformed,atrial
of angiotensin converting enzyme inhibitor or angiotensin
receptor blocker has been advocated under close supervision
by an experienced specialist in a tertiary hospital [98, 99].
9.4. Hypertension in Chronic Kidney Disease (CKD). Hyper-
tension is a common occurrence in CKD increasing in sever-
ity with worsening in renal function. Both renoparenchymal
diseases and tubulointerstitial diseases lead to renal scarring
and reduction in nephron mass which results in activation
of RAAS. The activation of RAAS leads to sodium and ﬂuid
retention and sympathetic hyperactivation contributing
to hypertension. Volume overload is the most important
factor leading to hypertension and hypertension-related
morbidity and mortality in patients with CKD. In addition
to the previous mechanism, several other factors like uremic
toxins, increased circulating endogenous NOS inhibitorsInternational Journal of Nephrology 11
like asymmetric dimethylarginine, secondary hyperparathy-
roidism leading to hypercalcemia, and increased expression
of endothelin A receptors have also been implicated
in the pathogenesis of hypertension in CKD. Maintaining
dry weight by strict volume control, dietary salt restriction,
and frequent dialysis will markedly reduce the need for anti-
hypertensive therapy. RAAS antagonist like ACE inhibitors
and ARB are considered as ﬁrst choice in the treatment
of hypertension in this group of patients. RAAS antagonists
not only lower transglomerular pressure and proteinuria
but also suppress cytokines and chemokine release. These
eﬀects confer nephroprotection by reduction in glomerular
hypertrophy and sclerosis and tubulointerstitial inﬂamma-
tion and ﬁbrosis. In addition to RAAS antagonist, calcium
channel blocker and beta-blockers are other therapeutic
options [100, 101].
9.5. Hypertension in Microangiopathies. Thromboticmi-
croangiopathy (TMA) is characterized by Coomb’s
negative microangiopathic hemolytic anemia (MAHA),
thrombocytopenia, and elevated lactate dehydrogenase
levels. Histopathologically the lesion is characterized by
endothelial injury and complete or partial obliteration of
the arteriolar lumen by ﬁbrin and platelet clots. Three types
of TMA have been described—Glomerular TMA, Acute
cortical necrosis and Arterial TMA—and have prognostic
value. Acute cortical necrosis type of TMA is irreversible,
glomerular TMA is partially reversible, and arterial TMA is
predominantly seen in adults, is associated with recurrence
or relapse and severe hypertension, and portends poor
prognosis. Similar histopathological lesions have been
described in conditions like Hemolytic-Uremic syndrome
(HUS), Thrombotic Thrombocytopenic Purpura (TTP),
and Hypertensive crisis of varied etiologies. Clinical features
of these conditions can overlap and may be diﬃcult to
distinguish one from another. In general, thrombocytopenia
is more severe in TMA induced by HUS/TTP compared
to TMA secondary to hypertensive crisis. Von Willebrand
factor cleaving protease enzyme (ADAMTS 13) deﬁciency is
frequently associated with TTP or atypical HUS and normal
in typical HUS. Renal involvement is common in all these
conditions. Hypertensive crisis can be the end result of renal
disease or can result in acute renal failure. HUS is one of
the most common causes of acute renal failure in childhood
and is characterized by a triad of Coomb’s negative MAHA,
thrombocytopenia, and acute renal failure. It has been
classiﬁed as typical or D+ HUS (diarrhea associated) or
atypical or DHUS (nondiarrhea associated). D+ HUS
is more common, frequently secondary to infectious
etiology like Shiga-toxin-producing enterohemorrhagic
Escherichia coli, Shigella dysenteriae type 1, and Streptococcus
pneumoniae, accounts for 90% of all cases, and carries
more favorable prognosis when compared to the atypical
HUS. Atypical HUS accounts for the remaining 10%
of cases and is secondary to genetic mutations in
the proteins involved in the regulation of alternative
complement pathway, or deﬁciency of Von Willebrand
factor cleaving protease enzyme (ADAMTS 13), and vitamin
B12 metabolic defects. Renal failure is common in both
typical and atypical HUS but the severity of the disease
and hypertension is more pronounced in atypical HUS.
Management of hypertension in these conditions includes
avoidance of volume overload and maintenance of
normal volume status, peritoneal dialysis or continuous
renal replacement therapy, and etiology-speciﬁc therapies.
In addition, in children with atypical HUS and TTP early
plasmapheresis and plasma exchange has been used with
variable results. Prolonged therapy with Eculizumab,
a monoclonal antibody against C5 preventing the formation
of membrane attack complex has been used in some
atypical HUS cases. In patients with HUS secondary to
vitamin B12 metabolic defects hydroxocobalamin therapy
has been advocated [102–105].
9.6.HypertensioninKidneyTransplantRecipients. Hyperten-
sion is common in pediatric patients with renal transplant
and occurs in up to 90% of the recipients. Hypertension
in postrenal transplant recipients increases the risks of
graft dysfunction and also cardiovascular morbidity and
mortality. Some of the important factors responsible for
the hypertension after renal transplant include preexist-
ing hypertension, native kidney disease, medications like
steroids,calcineurininhibitors,bothcoldandwarmischemia
times, graft dysfunction, renal artery stenosis, thrombotic
microangiopathy, and postbiopsy arteriovenous ﬁstula, The
pathogenesis of the hypertension includes sodium and water
retention, activation of RAAS, sympathetic overactivity,
inhibition of atrial natriuretic peptide, imbalance in the
synthesis and degradation of Nitric Oxide, endothelial dys-
function, and oxidative stress. In general, the hypertension
induced by cyclosporine is more severe when compared
to tacrolimus. Management of hypertension in this group
of patients includes close monitoring of the drug levels
of immunesuppressive medications like cyclosporine and
tacrolimus and using least amount of medication or switch-
ing to another medication (like cyclosporine to tacrolimus
or sirolimus) needed for graft survival. Monitoring for
drug interactions and avoiding or minimizing medications
can increase the serum levels of the immune-suppressive
medications. Calcium-channel blockers decrease the vaso-
constriction induced by the calcineurin inhibitors and are
considered in the management of hypertension in these
patients. However, care should be taken in monitoring the
levels of cyclosporine and tacrolimus as some of the CCB
like diltiazem, verapamil, and nicardipine are known to
interfere with the drug metabolism. In addition, thiazide
and loop diuretics, ACE inhibitors, and ARB are also
used either alone or in combination with control resistant
hypertension. ACE inhibitors and ARB because of their
antiproteinuric and antierythrocytosis eﬀect are particularly
useful. However, they can cause decrease in GFR and cause
anemia and potentiate hyperkalemia. These medications
should be avoided in patients with decreased GFR secondary
to graft dysfunction and also in patients with posttransplant
renalarterystenosis.Minoxidilmaybeconsideredinpatients
with tacrolimus-induced alopecia [106–108].12 International Journal of Nephrology
10. Conclusions
Hypertensive crisis is an important pediatric emergency
associated with signiﬁcant morbidity and mortality. Early
diagnosis, aggressive but careful management depending
on speciﬁc etiologies, and long-term follow-up will help
in decreasing some of this burden. Both basic and clinical
research eﬀorts to further delineate risk factors, patho-
physiology, and epidemiology should be prioritized. Thus
improved knowledge will contribute to better therapies.
Dietary and lifestyle modiﬁcations do not seem as important
as the implementation of guidelines and policies in changing
the prognosis of hypertensive crisis.
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